Innovative Serological Test and Treatment strategies for accelerating P. vivax malaria elimination in the Latin America region (webinar)

P. vivax elimination is challenging due to the parasite’s ability to relapse from dormant liver-stages. Serological biomarkers have been validated as sensitive and specific indicators of exposure to P. vivax blood-stage infections within the prior 9 months and serve as surrogate indicators for identifying individuals at risk of relapse. They thus offer new possibilities for interventions specially targeting and preventing relapses. Building on this evidence, the P. vivax Serological Testing and Treatment (PvSeroTAT) strategy has emerged as a potential tool to strengthen national malaria elimination efforts in P. vivax-endemic settings.

This webinar focused on:

• The PvSeroTAT Approach: Understanding the theory and evidence underpinning P. vivax Serological Testing and Treatment strategies.
• Key Findings: Insights from recent research on the use of serological relapse risk biomarkers to enhance and accelerate P. vivax elimination strategies.
• Operational Feasibility: Practical applications and lessons learned from implementing PvSeroTAT in different vivax-endemic contexts. For example, the use of PvSeroTAT as an outbreak response tool or for reactive case detection
• Future Directions: Next steps in the product development pipeline and priorities for scaling serological tools.
• The Vivax Serology Partnership: Overview of the partnership’s goals and opportunities for collaboration and involvement.